

Accepted Manuscript

First-in-Human Phase I Study of AC0010, a Mutant-Selective EGFR Inhibitor in Non-Small Cell Lung Cancer: Safety, Efficacy, and Potential Mechanism of Resistance

Yuxiang Ma, Xin Zheng, Hongyun Zhao, Wenfeng Fang, Yang Zhang, Jieying Ge, Lu Wang, Weicong Wang, Ji Jiang, Shaokun Chuai, Zhou Zhang, Wanhong Xu, Xiao Xu, Pei Hu, Li Zhang

PII: S1556-0864(18)30264-8

DOI: [10.1016/j.jtho.2018.03.025](https://doi.org/10.1016/j.jtho.2018.03.025)

Reference: JTHO 921

To appear in: *Journal of Thoracic Oncology*

Please cite this article as: Ma Y, Zheng X, Zhao H, Fang W, Zhang Y, Ge J, Wang L, Wang W, Jiang J, Chuai S, Zhang Z, Xu W, Xu X, Hu P, Zhang L, First-in-Human Phase I Study of AC0010, a Mutant-Selective EGFR Inhibitor in Non-Small Cell Lung Cancer: Safety, Efficacy, and Potential Mechanism of Resistance, *Journal of Thoracic Oncology* (2018), doi: 10.1016/j.jtho.2018.03.025.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1 **TITLE: First-in-Human Phase I Study of AC0010, a Mutant-Selective EGFR Inhibitor**
2 **in Non-Small Cell Lung Cancer: Safety, Efficacy, and Potential Mechanism of**
3 **Resistance**

4 **AUTHORS AND AFFILIATIONS:** Yuxiang Ma^{1*}, Xin Zheng^{2*}, Hongyun Zhao^{1*}, Wenfeng
5 Fang¹, Yang Zhang¹, Jieying Ge¹, Lu Wang², Weicong Wang², Ji Jiang², Shaokun Chuai³,
6 Zhou Zhang³, Wanhong Xu⁴, Xiao Xu⁵, Pei Hu² & Li Zhang¹

7 *These authors contributed equally to this paper.

8 ¹Department of medical oncology, Sun Yat-sen University Cancer Center, State Key
9 Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer
10 Medicine, Guangzhou, China; ²Clinical Pharmacology Research Center, Peking Union
11 Medical College Hospital, Beijing, China; ³Burning Rock Biotech, Guangzhou, China;
12 ⁴ACEA Pharmaceutical Research, Hangzhou, China; ⁵ACEA Biosciences Inc., San Diego,
13 USA

14 **CORRESPONDING AUTHOR:**

15 Li Zhang

16 Department of medical oncology

17 Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China,
18 Collaborative Innovation Center for Cancer Medicine

19 #651 Dongfeng East Road, Guangzhou 510060, China

20 Phone: 86 020 87343822

21 Fax: 86 020 87343786

22 E-mail: zhangli@sysucc.org.cn

23 **RUNNING TITLE:** Phase I study of EGFR inhibitor AC0010 in NSCLC

24 **FUNDINGS:** This work was supported by National Key R&D Program of China (grant
25 number: 2016YFC0905500), Chinese National Natural Science Foundation project (Grant No.
26 81372502), Science and Technology Program of Guangzhou, China (Grant No.
27 201607020031) and ACEA Pharmaceutical Research, ACEA Biosciences Inc., Burning Rock
28 Biotech.

29 **Disclosures:** Li Zhang: research funding from Bristol-Myers Squibb, Pfizer, Eli Lilly, ACEA
30 Pharmaceutical Research. Yuxiang Ma: travel expenses from ACEA Pharmaceutical
31 Research. Shannon Chuai, Zhou Zhang: employee and stock owner of Burning Rock Biotech.
32 Wanhong Xu: employee and stock owner of ACEA Pharmaceutical Research. Xiao Xu: CEO,
33 Co-founder and stock owner of: ACEA Biosciences Inc. All remaining authors have declared
34 no conflicts of interest.

35 Presented, in part, at Annual Meeting of European Society for Medical Oncology as oral
36 presentation in Developmental therapeutics Session (Abstract Number: 1623), Copenhagen
37 Denmark, November 2016.

38

Download English Version:

<https://daneshyari.com/en/article/8787570>

Download Persian Version:

<https://daneshyari.com/article/8787570>

[Daneshyari.com](https://daneshyari.com)